MedTrace Logo

PRV-3279-2a Trial in Systemic Lupus

NCT05087628 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-03

Study results available
· View outcomes & findings →

Summary

The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.

Conditions

Interventions

BIOLOGICAL

PRV-3279

Bi-specific antibody-based molecule

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Provention Bio, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2024-05-14
Completion
2024-06-24
FDA Drug
Yes

Countries

  • United States
  • China
  • Hong Kong
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05087628 on ClinicalTrials.gov